论文 · 动物实验
靶向间日疟原虫E140抗原的mRNA-脂质纳米颗粒疫苗
An mRNA-lipid nanoparticle vaccine targeting the Plasmodium vivax E140 antigen
作者：Rodolfo Ferreira Marques, Guilherme Antonio de Souza-Silva, Vitor Antunes da Silva, András Sárközy, Máté Vadovics, Hiromi Muramatsu, Edit Ábrahám, Carolina Bioni Garcia, Silvia Beatriz Boscardin, Rachel H J Jun, Anna Caroline Campos Aguiar, Zoltan Lipinszki 等 14 人
Mol Ther Nucleic Acids · 2026年9月2日 · Marques 等 14 位作者
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Plasmodium vivax (Pv) remains the primary cause of malaria outside Africa, yet no licensed vaccine is available against this pathogen. Here, we evaluate the immunogenicity and protective efficacy of novel vaccines targeting E140, a recently identified multi-stage antigen conserved across Plasmodium species. Lipid nanoparticle (LNP)-formulated nucleoside-modified mRNA vaccines against P. berghei E140 (PbE140) and P. vivax E140 (PvE140) induced robust antigen-specific IgG antibody responses, germinal center B cell, and long-lived plasma cell responses. Vaccination with PbE140 mRNA-LNP resulted in reduced parasitemia and improved survival in pathogen-challenged mice. Importantly, antibodies elicited by PvE140 mRNA-LNP in mice reduced invasion of primary human reticulocytes by P. vivax merozoites by 56%-78% in ex vivo functional assays. These findings suggest that E140 may be a promising antigen candidate for next-generation vaccines against P. vivax.
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。